Sanofi-Aventis

In 2000 the foundation was renamed the Aventis Foundation subsequent to the 1999 merger of Hoechst and Rhône-Poulenc. Photo Credit: internuggler. The Aventis Prizes are managed by the Royal Society, the UK national academy of science, and the Aventis Foundation, a German charitable trust established in 1996 as the Hoechst Foundation with an endowment of €50 million. He was enshrined in the Basketball Hall of Fame on September 10, 2004. The Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, have grown to be one of the world's most prestigious non-fiction literary prizes. Drexler's #22 jersey has been retired by both the Rockets and the Trail Blazers. Research and development investment was €4 bn. Drexler retired from the NBA after the 1997-'98 season in order to become head coach at his alma mater, the University of Houston, where he first gained fame playing with Hakeem Olajuwon, his future Rockets teammate.

It has operations in more than 100 countries throughout the 5 continents and has 99,700 employees worlwide. Drexler helped the Rockets to win the NBA title in 1995, and stayed with them for three more years. In 2003, Sanofi-Aventis's consolidated sales was €25 bn. On February 14, 1995, he was traded by the Blazers to the Houston Rockets, and immediately the Rockets, who were struggling to regain the championship form they had a year earlier, turned around. Dehecq has been the General Manager of Sanofi since its creation in 1973. Olympics basketball team, nicknamed The Dream Team, and won a gold medal in the process. The merged company was based in Strasbourg, France. In 1992 he served for the U.S.

merged with Hoechst Marion Roussel, in turn formed merging Hoechst AG with Roussel and Marion Merrell Dow. He helped lead that team to the NBA Finals in 1990 and 1992. Aventis was formed in 1999 when Rhône-Poulenc S.A. He attended the University of Houston and was drafted 14th overall in the 1983 NBA Draft by the Portland Trail Blazers. The merged company was based in Paris, France. Clyde Austin "The Glide" Drexler (born June 22, 1962 in New Orleans, Louisiana) is a former NBA all-star guard. Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo. Basketball Hall of Famer (2004).

French government, desiring a local merger solution, put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running. Named one of the 50 Greatest Players in NBA History (1996). Government intervention also played an active role. 1 NBA championship (1995). The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. Olympic gold medalist (1992). Initially, Aventis rejected the bid because it offered inferior value based on the company's share value. All-NBA First Team (1992).

In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn against Aventis. All-NBA Second Team (1988, '91). Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo merged with Aventis. 10-time NBA All-Star (1986, '88, '89, 90, '91, '92, '93, '94, '96, '97). . Sanofi-Aventis covers 7 therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

Sanofi-Aventis engages in the research, development, manufacture and marketing of pharmaceutical products for sale principlally in the presciption market. Sanofi-Aventis (Euronext:FR0000120578) (NYSE:SNY), headquartered in Paris, France, is the world's number 3 company in the pharmaceutical industry (behind Pfizer and GlaxoSmithKline, but above Merck and AstraZeneca). Yahoo! - Sanofi-Aventis Company Profile. Sales by geographic area breakdown: 58% from Europe, 24% from US, 18% from rest of the world.

Sales by activity breakdown: 39% from Cardiovascular/Thrombosis, 29% from Central Nervous System, 18% from Internal Medicine, 11% from Oncology, 3% from other pharmaceutical products. Voting right distribution: 21.37% to Total, 17.12% to L'Oréal, 1.54% to employees, and 59.97% to the public. Breakdown of share ownership: 12.65% by Total SA, 10.13% by L'Oréal, 5.47% treasury shares, 1.29% employees, the remaining 70.46% are publicly traded. Gérard Le Fur, Senior EVP.

Jean-François Dehecq, Chairman and CEO.